These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18703395)

  • 21. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B
    Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm.
    Gaston RS
    Clin J Am Soc Nephrol; 2009 Dec; 4(12):2029-34. PubMed ID: 19850771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Minimization or avoidance of calcineurin inhibitors after renal transplantation].
    Xue C; Ji ZG
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Jun; 31(3):280-3. PubMed ID: 19621509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure.
    González-Vílchez F; de Prada JA; Exposito V; García-Camarero T; Fernández-Friera L; Llano M; Ruano J; Martín-Durán R
    J Heart Lung Transplant; 2008 Oct; 27(10):1135-41. PubMed ID: 18926406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Monitoring of calcineurin inhibitors induced-nephrotoxicity].
    Kamar N; Rostaing L
    Nephrol Ther; 2008 Jun; 4 Suppl 1():S13-S17. PubMed ID: 18703392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calcineurin nephrotoxicity.
    Williams D; Haragsim L
    Adv Chronic Kidney Dis; 2006 Jan; 13(1):47-55. PubMed ID: 16412970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunosuppression in renal transplantation: some aspects for the modern era.
    Chadban S; Morris R; Hirsch HH; Bunnapradist S; Arns W; Budde K
    Transplant Rev (Orlando); 2008 Oct; 22(4):241-51. PubMed ID: 18657962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sirolimus in renal transplantation.
    Morath C; Arns W; Schwenger V; Mehrabi A; Fonouni H; Schmidt J; Zeier M
    Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii61-viii65. PubMed ID: 17890266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late conversion to everolimus complicated with necrotizing glomerulonephritis in a renal allograft recipient: case report.
    Nowacka-Cieciura E; Perkowska-Ptasińska A; Sulikowska-Rowińska A; Cieciura T; Wazna E; Durlik M
    Transplant Proc; 2009; 41(1):441-5. PubMed ID: 19249576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modern approaches to combining sirolimus with calcineurin inhibitors.
    Stevens RB
    Transplant Proc; 2008 Dec; 40(10 Suppl):S21-4. PubMed ID: 19100901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.
    Demirjian S; Stephany B; Abu Romeh IS; Boumitri M; Yamani MH; Poggio ED
    Clin Transplant; 2009; 23(3):351-60. PubMed ID: 19208105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can mTOR inhibitors reduce the risk of late kidney allograft failure?
    Ponticelli C
    Transpl Int; 2008 Jan; 21(1):2-10. PubMed ID: 17635837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Side effects of proliferation signal inhibitors and their management].
    Epailly E; Lorho R
    Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S268-74. PubMed ID: 20004334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in human leukocyte antigen (HLA)-identical live donor renal transplantation.
    Walker JK; Alloway RR; Roy-Chaudhury P; Mogilishetty G; Cardi MA; Weimert NA; Rike AH; First MR; Woodle ES
    Transplantation; 2009 Feb; 87(3):408-14. PubMed ID: 19202447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. mToR inhibitors-induced proteinuria: mechanisms, significance, and management.
    Letavernier E; Legendre C
    Transplant Rev (Orlando); 2008 Apr; 22(2):125-30. PubMed ID: 18631865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for immunosuppression in lung transplantation.
    Hopkins PM; McNeil K
    Curr Opin Organ Transplant; 2008 Oct; 13(5):477-83. PubMed ID: 19060529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic monitoring of calcineurin inhibitors for the nephrologist.
    Schiff J; Cole E; Cantarovich M
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):374-84. PubMed ID: 17699437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
    Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.